• Siemens and Jinyu Bio signed a strategic cooperation agreement to deepen cooperation
• Siemens helps Jinyu Bio to build a digital factory for Industry 4.0 with its pharmaceutical digital enterprise solution
• Both parties signed software and engineering contracts for the SimaTIc IT eBR and Comos platforms
Siemens signed a strategic cooperation agreement with Jinyu Biotechnology Co., Ltd. (Jinyu Bio) on January 7th, which will help Jinyu Bio to build an intelligent industrial park facing “Industry 4.0†and create a world-class biotechnology with Siemens' advanced digital enterprise solutions. Science and Technology Industrial Park. Wang Bo, vice chairman of the Inner Mongolia Autonomous Region, Li Jiexiang, mayor of Hohhot, and Bi Guochen, deputy mayor, attended the ceremony and witnessed the signing ceremony.
Siemens and Jinyu Bio will work closely together in the key areas of “Industry 4.0†such as automation, digitization and intelligence, and strive to open up the R&D, production and quality control of the enterprise to realize project management, equipment operation and maintenance, environmental monitoring, energy conservation and emission reduction. Digitizing. Under the agreement, Siemens will provide Jinyu Bio with a range of products, systems and related solutions and technical support to help it achieve plant intelligence, including the overall planning of the park, industrial information security and network systems, intelligent production systems, building management, energy Management, laboratory management systems, etc. At present, Siemens and Jinyu Bio have signed software and engineering contracts for the pharmaceutical industry manufacturing execution system SimaTIc IT eBR and engineering design and operation management platform Comos, introducing Siemens SimaTIc fully integrated production management system and “integrated engineering to integrated operation and maintenance†Advanced digital design concept.
“Jinyu Biotechnology Co., Ltd. is one of Siemens' most important partners in the pharmaceutical industry.â€
Lin Bin, Executive Vice President of Process Industry and Drives Group, Siemens (China) Co., Ltd. said, “Digitalization is the only way to get to 'Industry 4.0' and 'Made in China 2025'. I believe that Siemens has cooperated with Jinyu Bio. The digital factory will become a model for the pharmaceutical industry and even the process industry digital factory, helping Jinyu Bio to achieve a comprehensive industrial transformation and upgrading."
"Siemens, as a leading company in digital enterprises, continues to provide quality products and advanced technical service solutions to the society with continuous technology and management innovation." Zhang Yuyu, chairman and president of Jinyu Biotechnology Co., Ltd., secretary of the party committee, said, "Jinyu Bio Adhering to the principle of innovation leading the future, integrating Siemens' technology and experience to establish a digital factory to form an intelligent manufacturing system will surely lead the digital development trend of the pharmaceutical industry to meet the needs of customers."
With the emphasis on the integrity of data in the pharmaceutical industry by global regulatory authorities, digitalization has become an increasingly topic of concern in the pharmaceutical industry, and is the only way for Chinese pharmaceutical companies to achieve transformation and upgrading. Siemens offers proven integrated digital solutions for the pharmaceutical industry, including SimaTIc IT eBR MES system, Comos engineering and equipment operation and maintenance management platform, Simatic PCS 7 process control system, Batch batch processing system, SIPAT process analysis solution , Scalance information security and industrial network and XHQ integrated information management platform, etc., and provide computerized system verification services that meet the requirements of FDA, EMEA, CFDA, etc. for this digital solution, helping Chinese pharmaceutical companies to improve quality and go global.
Jinyu Bio is a leading company in the veterinary biological products industry in China. It has become the industry standard in product quality and testing. Its own product quality standards have always been higher than industry standards, in large-scale mammalian cell culture, recombinant protein purification. And there is considerable technical accumulation in the verification. In 2015, Jinyu Bio was ranked first in the Chinese foot-and-mouth disease vaccine market, with a direct sales share of 60%. At present, Jinyu Biotech invested 5 billion yuan in Hohhot to build Jinyu Biotechnology Industrial Park with a total construction area of ​​330,600 square meters, which will form four major bio-pharmaceutical, veterinary bio-pharmaceutical, Sino-foreign joint venture life science, and R&D supporting services. Functional area, creating a technical support and incubation platform.
Zoolied has a large quantity of 150 mm Silicon Wafers in stock in P(100), N(100), P(111), and N(111) types & orientations. Prime, Test, Reclaim Test, and Dummy grades are available. Below is a sample of some of the silicon wafers we have in stock. We also currently have 150 mm silicon wafers with SiO2 coatings in stock. Contact us for details.
6 Inch Silicon Wafers,6 Silicon Wafer,Thin Silicon Wafers,Silicon Wafer Dicing
Zoolied Inc. , https://www.zoolied.com